NCT00783432

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 862 (actual)
• Sponsor: Meda Pharmaceuticals · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)

Conditions

• Chronic Allergic Rhinitis
• Nonallergic Rhinitis

Interventions

Type	Name	Description
DRUG	Astepro Nasal Spray (0.1% azelastine hydrochloride)	548 mcg (2 sprays per nostril) twice a day
DRUG	Astelin Nasal Spray (0.1% azelastine hydrochloride)	548 mcg (2 sprays per nostril) twice a day

Timeline

• Start date: 2006-07-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2008-10-31
• Last updated: 2009-10-06
• Results posted: 2009-10-02

Locations

1 site across 1 country: United States